Pila Pharma recently strengthened its scientific advisory board with a significant addition: Professor Thomas Lutz, a renowned expert in metabolic research and the pancreatic hormone amylin. As the company approaches key preclinical proof-of-concept results for its candidate XEN-D0501, BioStock reached out to Professor Lutz to discuss his decision to join, his view on the obesity market, and the potential of Pila Pharma's novel approach.

Read the full article at biostock.se:
https://biostock.se/en/2025/12/pila-pharmas-nya-vetenskaplige-radgivare-kommenterar-utvecklingen-inom-fetmaomradet/
This is a press release from BioStock - Connecting Innovation & Capitalhttps://www.biostock.se

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!  

About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital. 

Läs mer på BioStock

Ämnen i artikeln

Pila Pharma

Senast

2,20

1 dag %

2,80%

1 dag

1 mån

1 år

Marknadsöversikt

OMX Stockholm 30

1 DAG %

0,14%

Senast

2 849,09

1 mån
Loading market data...